According to information received by Zhito Finance App, Helen Torley, CEO of Halozyme therapeutics (HALO.US), stated that the company plans to finance 2 billion euros (approximately 2.1 billion dollars) in cash to acquire the German company Evotec (EVO.US). Torley stated in an interview: "We are confident in funding this deal with a full cash trade. We will not use equity." She added: "Due to some debt we have taken on, our strong cash flow will be able to quickly reduce our leverage to two times after the deal is completed."

It is reported that Halozyme therapeutics, headquartered in San Diego, expects to fund part of the acquisition with approximately 0.6 billion dollars in cash on hand and remaining debt. Torley added that the company is finalizing debt financing with potential bank lenders.

The automated injection devices produced by Halozyme therapeutics can deliver large amounts of medication to patients more quickly. Its pharmaceutical partners include Johnson & Johnson (JNJ.US) and Bristol-Myers Squibb (BMS). Meanwhile, Evotec will assist pharmaceutical companies in selecting molecules for further development and drug production.

It is reported that the private equity firm Triton Partners has disclosed its holdings in Evotec and has been considering initiating a buyout. The report quoted Torley as saying: "We believe this is a good way to enhance Halozyme therapeutics' already strong revenue growth story." "We already have drug delivery, which will lead to drug discovery and production."